FDA Inspection 1090411 — Sentynl Therapeutics, Inc.
The FDA completed an inspection of Sentynl Therapeutics, Inc. on May 10, 2019 in Solana Beach, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 10, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Solana Beach, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)